CAROL A TAMMINGA
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry DALLAS, TX NPI 1609831759
Browse related groups: Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry TX Aurobindo Pharma USA, Inc. All categories
General Payments — all program years on this page
$44,140.22
- Category: General Payments
- Program years: PY2018–2024
- Record count: 48
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $8,711.70 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $8,655.43 | 5 |
| Food and Beverage | $42.00 | 2 |
| Travel and Lodging | $14.27 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Aurobindo Pharma USA, Inc. | $3,710.95 | 3 |
| E.R. Squibb & Sons, L.L.C. | $2,500.00 | 1 |
| Merck Sharp & Dohme Corporation | $2,487.50 | 3 |
| Mylan Inc. | $13.25 | 1 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1101645382 | E.R. Squibb & Sons, L.L.C. | $2,500.00 | 12/02/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1141587164 | Merck Sharp & Dohme LLC | $700.00 | 04/24/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1141809133 | Merck Sharp & Dohme LLC | $1,462.50 | 01/24/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1141809135 | Merck Sharp & Dohme LLC | $325.00 | 12/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1147272492 | Mylan Inc. | $13.25 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1152937303 | Aurobindo Pharma USA, Inc. | $3,667.93 | 10/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1152942203 | Aurobindo Pharma USA, Inc. | $14.27 | 10/10/2024 | Travel and Lodging | Undisputed | 01/23/2026 | View at CMS |
| 1153991435 | Aurobindo Pharma USA, Inc. | $28.75 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.